Compare UHT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | DRUG |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.5M | 707.1M |
| IPO Year | 1995 | 2020 |
| Metric | UHT | DRUG |
|---|---|---|
| Price | $42.61 | $90.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $43.00 | ★ $129.25 |
| AVG Volume (30 Days) | 51.3K | ★ 142.5K |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $33.52 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $23.18 |
| 52 Week High | $44.70 | $123.75 |
| Indicator | UHT | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 67.59 |
| Support Level | $41.96 | $69.83 |
| Resistance Level | $43.22 | $91.00 |
| Average True Range (ATR) | 0.78 | 4.46 |
| MACD | 0.14 | 1.50 |
| Stochastic Oscillator | 71.17 | 92.08 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.